Pharmacokinetics of Intramuscularly Administered Ketamine at Subanaesthetic Dosage in Horses

Read full text Summarise with VIRAT
Authors: Zoë Vandaele, Jana Flyps, Charlotte Cuypers, Siegrid De Baere, Mathias Devreese, Stijn Schauvliege
Cited by: 0
References: 30

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Subanaesthetic doses of ketamine (0.5 mg kg −1 ) provide analgesia in several species, but there is limited information on the pharmacokinetics and clinical effects of intramuscularly administered ketamine in horses. This study investigated the pharmacokinetics of ketamine and norketamine, and evaluated clinical effects, ataxia, and vital parameters, following intramuscular and intravenous administration of 0.5 mg kg −1 ketamine in nine healthy horses, using a randomized two‐period crossover design with a 1‐week washout period. Plasma concentrations were analyzed using Ultra‐High Performance Liquid Chromatography–Tandem Mass Spectrometry (UHPLC–MS/MS). Ketamine pharmacokinetic parameters were calculated using a one‐compartment model and norketamine using a noncompartmental model. After intravenous administration ( n = 9), ketamine showed a C max of 525 ± 290 ng mL −1 , an AUC 0–∞ of 85.9 ± 54.7 ng·h mL −1 , and a t 1/2z of 0.1 ± 0.01 h. Following intramuscular administration ( n = 7), ketamine plasma concentrations were below the limit of quantification (< 5 ng mL −1 ) except at a few early timepoints, preventing reliable pharmacokinetic analysis. Norketamine showed a C max of 39.7 ± 32.3 ng mL −1 and a t max of 0.3 ± 0.18 h after intramuscular administration. All horses developed transient, mild‐to‐severe ataxia after intravenous administration, resolving within 15 min. This was not observed after intramuscular administration. Intramuscular ketamine administration (0.5 mg kg −1 ) shows a low systemic bioavailability (< 5%) but is well tolerated and has minimal adverse effects.

Fields of Study & Subjects

Veterinary Pharmacology and Anesthesia Veterinary Equine Medical Research Anesthesia and Sedative Agents

Publication details

Journal / source
Journal of Veterinary Pharmacology and Therapeutics
Volume
49
Issue
4
Pages
392–401
Publication date
31 March 2026
Language
EN